Charles Schwab Investment Management Inc. Raises Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

Charles Schwab Investment Management Inc. boosted its position in RxSight, Inc. (NASDAQ:RXST) by 28.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 285,329 shares of the company’s stock after purchasing an additional 62,507 shares during the period. Charles Schwab Investment Management Inc. owned about 0.77% of RxSight worth $14,104,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. CWM LLC boosted its holdings in RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares during the period. Nisa Investment Advisors LLC boosted its stake in RxSight by 854.1% during the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares during the period. Quest Partners LLC purchased a new position in shares of RxSight during the second quarter valued at approximately $41,000. KBC Group NV boosted its stake in shares of RxSight by 63.6% during the third quarter. KBC Group NV now owns 1,232 shares of the company’s stock valued at $61,000 after purchasing an additional 479 shares during the period. Finally, Amalgamated Bank raised its stake in shares of RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after acquiring an additional 207 shares in the last quarter. 78.78% of the stock is currently owned by institutional investors.

RxSight Stock Performance

Shares of RxSight stock opened at $43.15 on Monday. RxSight, Inc. has a fifty-two week low of $33.09 and a fifty-two week high of $66.54. The company has a market cap of $1.74 billion, a P/E ratio of -51.99 and a beta of 1.11. The firm has a 50-day simple moving average of $48.01 and a two-hundred day simple moving average of $51.53.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Jefferies Financial Group initiated coverage on RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and set a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Finally, UBS Group began coverage on shares of RxSight in a research report on Friday. They set a “buy” rating and a $52.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, RxSight currently has a consensus rating of “Buy” and an average price target of $63.63.

Insider Buying and Selling

In other RxSight news, Director Shweta Maniar sold 3,782 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total value of $173,518.16. Following the transaction, the director now owns 10,902 shares in the company, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Ilya Goldshleger sold 3,105 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $46.08, for a total transaction of $143,078.40. Following the completion of the sale, the insider now owns 42,246 shares of the company’s stock, valued at approximately $1,946,695.68. The trade was a 6.85 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 65,807 shares of company stock valued at $3,202,275. 9.36% of the stock is owned by company insiders.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.